Saturday 17 October 2026
Export ARGX’s income statement to Excel — free account
argenex SE
ARGX Healthcare Biotechnology
argenex SE’s revenue for fiscal 2025 (year ended December 2025) was $4.2 billion, up 88.6% from fiscal 2024. In the quarter to June 2026, revenue grew 59.5%, EPS grew 88.6% and free cash flow grew 537.5%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.
819.14
27.13
−3.21%
Follow ARGX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
33.47 | 30.23 | 39.97 | 29.27 |
+8 more quarters Free account |
P/S ratio |
10.85 | 9.53 | 12.13 | 12.28 | |
P/FCF ratio |
41.94 | 77.00 | 87.59 | 0.00 | |
P/Operating CF |
0.00 | 0.00 | 0.00 | 0.00 | |
P/B ratio |
6.87 | 6.19 | 7.04 | 7.43 | |
Price to Tangible BV |
7.09 | 6.43 | 7.31 | 7.70 | |
EV/Sales |
10.18 | 8.80 | 11.31 | 11.71 | |
EV/EBITDA |
33.86 | 31.96 | 45.61 | 54.72 | |
EV/Operating CF |
33.57 | 49.81 | 57.23 | (162.51) | |
EV/FCF |
39.34 | 71.08 | 81.66 | (96.14) | |
Quick Ratio |
3.51 | — | 3.90 | — | |
Current Ratio |
5.12 | — | 5.23 | — | |
Net Debt/EBITDA |
(7.26) | 0.00 | (9.50) | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | — | 0.00 | — | |
Asset Turnover |
0.72 | 0.00 | 0.64 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
(0.47) | — | (3.97) | — | |
Interest Coverage |
494.00 | 394.00 | 337.57 | 348.63 | |
Research and Development Expense of Revenue |
31.52% | 33.74% | 27.78% | 30.89% | |
Selling, General and Administrative Expense of Revenue |
27.04% | 27.04% | 32.49% | 29.21% | |
Intangible Assets out of Total Assets |
0.03 | 0.00 | 0.03 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
0.11 | 0.12 | 0.11 | 0.10 | |
Graham Number |
290.25 | 0.00 | 237.82 | 0.00 | |
Earnings Yield |
2.99% | 3.31% | 2.50% | 3.42% | |
Free Cash Flow Yield |
2.38% | 1.30% | 1.14% | (0.99%) | |
Revenue per Share |
24.75 | 21.16 | 21.58 | 18.76 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Cash per Share |
57.52 | 0.00 | 56.95 | 0.00 | |
Shareholders Equity per Share |
135.08 | 0.00 | 119.47 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
135.08 | 0.00 | 119.47 | 0.00 | |
Free Cash Flow |
643.00 | — | 573.51 | — | |
Working Capital |
6,493.00 | — | 5,579.00 | — | |
Capital Expenditures |
(8.00) | — | (111.68) | — | |
Net Current Asset Value |
6,453.00 | — | 5,539.00 | — | |
EV/EBIT |
33.86 | 31.96 | 45.61 | 54.72 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
36.09 | 34.62 | 48.91 | 57.35 | |
| Other line items | |||||
Average Receivables |
1,298.28 | — | 1,078.14 | — | |
Average Payables |
997.41 | — | 840.51 | — | |
Average Inventory |
348.73 | — | 392.28 | — | |
Average Assets |
7,414.28 | 0.00 | 6,612.73 | 0.00 | |
Average Common Equity |
6,339.62 | — | 5,710.25 | — |
Columns are period end dates